![Page 1: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/1.jpg)
TITLE from VIEW and SLIDE MASTER | 26 October 2016 1 |
Strategies regarding new high cost biological
medicines when developing formularies across the Interface
Interface Management of Pharmacotherapy
Barcelona – 17th October 2016
NICOLA MAGRINI
ESSENTIAL MEDICINES AND HEALTH PRODUCTS DEPARTMENT
![Page 2: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/2.jpg)
TITLE from VIEW and SLIDE MASTER | 26 October 2016 2 |
Strategies on the selection of high priced medicines
NICOLA MAGRINI
POLICY, ACCESS AND USE ESSENTIAL MEDICINES AND HEALTH PRODUCTS DEPARTMENT
What I’ll speak about
![Page 3: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/3.jpg)
HIS/EMP | Communications Planning HIS | EMP
Contents of the presentation
• WHO EML: a quick history • EML 2015 update and high priced medicines • The WHO strategy on
– Pharmacological class, therapeutic equivalency (EML square box) – Generics and biosimilars – Other options
![Page 4: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/4.jpg)
First EML: 1977 36 pages, 20 references
![Page 5: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/5.jpg)
EML 1977: early evidence-based adopter
No medicines for: • Memory loss and dementia • Hepatoprotectants • Immunostimulants
• No medicines listed subsequently
withdrawn for unexpected risks (e.g., cox-2 inhibitors)
• Important medicines for: – Antibiotics – Neglected diseases – Pain – Mental health – Chronic diseases – Cancer
• Concise and clear • Promoting uptake of best
research findings on medicines into healthcare and national policies
![Page 6: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/6.jpg)
Essential Medicines List: Concept and Procedures 6 |
Essential Medicines
Guiding principle: A limited range of carefully selected medicines leads to better health care, better medicines management, and lower costs
Definition: Essential medicines are those that satisfy the priority health care needs of the population
Selection: Selected with due regard to disease prevalence, evidence on efficacy and safety, and comparative cost-effectiveness
![Page 7: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/7.jpg)
Essential Medicines List: Concept and Procedures 7 |
EML criteria (EB 109/8, 2001)
Disease burden and public health need/relevance
Sound and adequate data on the efficacy (on relevant outcomes), safety and comparative cost-effectiveness
– “Absolute cost of the treatment will not constitute a reason to exclude a medicine from the Model List that otherwise meets the stated selected criteria”
– “Affordability changed from a precondition into a consequence of the selection” (Hogerzeil, BMJ, 2004)
WHO responsible management and oversight of CoIs
2008 WHO new Guideline Manual, adopting GRADE
Considering also: regulatory status / availability, WHO guidelines
![Page 8: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/8.jpg)
Essential Medicines List: Concept and Procedures 8 |
19th EML & 5th EMLc - 2015
19th EML: 409 medicines – 5th EMLc (children): 294 medicines
586 pages, 1082 references
![Page 9: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/9.jpg)
Essential Medicines List: Concept and Procedures 9 |
EML 2015: tough decisions
![Page 10: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/10.jpg)
Essential Medicines List: Concept and Procedures 10 |
EML 2015: 77 applications and a few big challenges Cancer drugs: a large comprehensive review led to 16 new
additions (including 2 mabs and imatinib)
New highly effective HCV drugs (all listed)
MDR-TB drugs (4) and 1 for TB prophylaxis
Rejections: New oral anticoagulants (NOACs), polypill(s), ranibizumab
![Page 11: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/11.jpg)
Essential Medicines List: Concept and Procedures 11 |
Lancet editorial October 24, 2015
![Page 12: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/12.jpg)
HIS/EMP | Communications Planning HIS | EMP
Contents of the presentation
• WHO EML: a quick history • EML 2015 update and high priced medicines • The WHO strategy on
– Pharmacological class, therapeutic equivalency (EML square box) – Generics and biosimilars – Other options
![Page 13: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/13.jpg)
Essential Medicines List: Concept and Procedures 13 |
EML and patented drugs
EML 2013: 20 out of 374 (5.4%)
EML 2015: 39 out of 409 (9.5%)
A trend?
Biosimilars: filgrastim, trastuzumab, rituximab
Next EML 2017?
![Page 14: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/14.jpg)
Objectives of phases I, II and III in drug registration : I: safety II: activity III: efficacy/effectiveness or B/R ratio
Drug registration and patent’s life
Patent expiry
![Page 15: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/15.jpg)
Drug’s life and life cycle well beyond patent: the next 20 years
Medicines’ life: longer than the patent
Life after patent expiry
![Page 16: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/16.jpg)
Essential Medicines List: Concept and Procedures 16 |
EML cancer medicines 2015 main criterion: magnitude of absolute benefits
Imatinib: vast majority of patients in remission at 7 yrs
Rituximab (large B cell lymphomas): 15% absolute increase in survival rates (from 50-55% to 70%)
Trastuzumab: early stage breast cancer: up to 13% increase in survival in high risk women (from 37% to 50% survival rates at 3-6 yrs)
Bendamustine, ATRA, …
Efficacy estimates applied to all proposed regimens
![Page 17: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/17.jpg)
Essential Medicines List: Concept and Procedures 17 |
![Page 18: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/18.jpg)
Essential Medicines List: Concept and Procedures 18 |
Imatinib generic prices 2016
![Page 19: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/19.jpg)
Imatinib prices 2013 - 2016
700 USD
![Page 20: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/20.jpg)
EML and pharmacological classes
Listing: one drug per pharmacological class … implications for selection and procurement
![Page 21: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/21.jpg)
Essential Medicines List: Concept and Procedures 21 |
EML and therapeutic equivalency 1/3
![Page 22: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/22.jpg)
Essential Medicines List: Concept and Procedures 22 |
EML and therapeutic equivalency 2/3
![Page 23: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/23.jpg)
Essential Medicines List: Concept and Procedures 23 |
Example 1
![Page 24: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/24.jpg)
Essential Medicines List: Concept and Procedures 24 |
Example 2 : limited square boxing
![Page 25: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/25.jpg)
Essential Medicines List: Concept and Procedures 25 |
Example 3: limited square boxing
![Page 26: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/26.jpg)
Essential Medicines List: Concept and Procedures 26 |
EML and therapeutic equivalency 3/3
WHO supports pooled procurement mechanisms that can increase competition among available alternatives/options
Generic substitution and biosimilars role
![Page 27: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/27.jpg)
HIS/EMP | Communications Planning HIS | EMP
Contents of the presentation
• WHO EML: a quick history • EML 2015 update and high priced medicines • The WHO strategy on
– Pharmacological class, therapeutic equivalency (EML square box) and tenders
– Generics and biosimilars – Other options
• ¨Conclusions
![Page 28: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/28.jpg)
Essential Medicines List: Concept and Procedures 28 |
Biosimilars: regulations still in progress
Recent documents
![Page 29: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/29.jpg)
Essential Medicines List: Concept and Procedures 29 |
![Page 30: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/30.jpg)
Essential Medicines List: Concept and Procedures 30 |
![Page 31: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/31.jpg)
Essential Medicines List: Concept and Procedures 31 |
![Page 32: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/32.jpg)
Essential Medicines List: Concept and Procedures 32 |
![Page 33: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/33.jpg)
Essential Medicines List: Concept and Procedures 33 |
![Page 34: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/34.jpg)
Essential Medicines List: Concept and Procedures 34 |
Biosimilars: no official WHO statement yet
INN, Biological standardisation and EML will be working together to define a WHO position
– Important implications on regulatory pathways, Therapeutic Committees and procurement
– Timeline: early (1st quarter) 2017?
![Page 35: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/35.jpg)
HIS/EMP | Communications Planning HIS | EMP
Contents of the presentation
• WHO EML: a quick history • EML 2015 update and high priced medicines • The WHO strategy on
– Pharmacological class, therapeutic equivalency (EML square box) and tenders
– Generics and biosimilars – Other options
• ¨Conclusions
![Page 36: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/36.jpg)
Public health, innovation and intellectual property 36 |
Policy options
Price controls: ‘Value-based pricing; price/volume agreements; pay for performance; risk-sharing agreement / patient access schemes; reference pricing schemes…
Differential pricing/price negotiations
Voluntary licensing agreements
Local production/import
TRIPS flexibilities, including compulsory licenses
![Page 37: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/37.jpg)
The Un High-level Panel on Access to Medicines
On 14th September 2015
![Page 38: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/38.jpg)
What’s in the UNHLP Report on access to medicines
• The report may spark controversy: • six panel members offered separate commentaries that either
criticized the panel for its timidity or chastised it for focusing too much on IP rights and not being fact driven.
• Some Member States have also voiced concerns about the process before the release of the report.
• Thus, it remains to be seen whether it will be discussed in the UN General Assembly, the WHO or another UN body.
![Page 39: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/39.jpg)
What’s in the UNHLP Report on access to medicines
• The report mentions positively a number of ongoing WHO initiatives – the WHO/DNDI Global Antibiotic R&D Partnership, – the (future) WHO/TDR voluntary pooled funding mechanism for R&D, – the R&D Blueprint.
• Some of the technical recommendations—in particular, the IP-related issues and the establishment of a database on medicine prices—are already within WHO’s mandate
![Page 40: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/40.jpg)
the UNHLP Report on access to medicines What’s new for WHO
• a database on medicine prices • Other recommendations would need endorsement by
member states, such as – the negotiation of international agreements – the SG’s establishment of an interagency task force.
![Page 41: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/41.jpg)
HIS/EMP | Communications Planning HIS | EMP
Contents of the presentation
• WHO EML: a quick history • EML 2015 update and high priced medicines • The WHO strategy on
– Pharmacological class, therapeutic equivalency (EML square box) and tenders
– Generics and biosimilars – Other options
• ¨Conclusions
![Page 42: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/42.jpg)
HIS/EMP | Communications Planning HIS | EMP
Conclusions EML, access and affordability
• Growing attention to the issue of access and affordability
• EML can play a role – Strong collaboration with MPP, – Fair pricing forum, – EML discussing thresholds for benefits – Biosimlars WHO GL in 2017
• together with all other stakeholders
![Page 43: Strategies regarding new high cost biological medicines ...€¦ · 1 | TITLE from VIEW and SLIDE MASTER | 26 October 2016. Strategies regarding new high cost biological medicines](https://reader033.vdocuments.site/reader033/viewer/2022060518/604b1d4ef1bfe8763d22e3ab/html5/thumbnails/43.jpg)
HIS/EMP | Communications Planning HIS | EMP
Questions? All questions are welcome
all questions can be useful to understand EML role and what I just presented